{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:13:19Z","timestamp":1784549599960,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008665","name":"Osaka Medical Research Foundation for Intractable Diseases","doi-asserted-by":"publisher","award":["30\\u20132\\u20139"],"award-info":[{"award-number":["30\\u20132\\u20139"]}],"id":[{"id":"10.13039\/501100008665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116684","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:48:32Z","timestamp":1773942512000},"page":"116684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phase Ia\/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)"],"prefix":"10.1016","volume":"238","author":[{"given":"Hiroaki","family":"Kanemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-9435","authenticated-orcid":false,"given":"Junko","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0590-9259","authenticated-orcid":false,"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0853","authenticated-orcid":false,"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-9776","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116684_bib1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","author":"Friedlaender","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib2","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","author":"Raghav","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer - an update","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116684_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable Activating Oncogenic ERBB2\/HER2 Transmembrane and Juxtamembrane Domain Mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116684_bib6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-Cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2026.116684_bib7","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","author":"Li","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116684_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib9","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I\/II Trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116684_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion\u2013positive metastatic non\u2013small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.1427","article-title":"P2.13-32 TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR\/HER2","volume":"13","author":"Chouitar","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib12","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic Drug Conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116684_bib14","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/0008-5472.CAN-21-1526","article-title":"Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib","volume":"81","author":"Han","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","article-title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2\/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial","volume":"4","author":"Borges","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib16","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.19.00858","article-title":"Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10","volume":"37","author":"Abraham","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib17","unstructured":"J\u00e4nne P.A., Wang B.-C., Cho B.C., Zhao J., Li J., Hochmair M., et al. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion\u2013Positive Metastatic Non\u2013Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology.0:JCO-24-01269."},{"key":"10.1016\/j.ejca.2026.116684_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116684_bib19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cpdd.951","article-title":"Single-Dose pharmacokinetics and tolerability of the oral epidermal growth factor receptor inhibitor mobocertinib (TAK-788) in healthy volunteers: low-fat meal effect and relative bioavailability of 2 capsule products","volume":"10","author":"Zhang","year":"2021","journal-title":"Clin Pharm Drug Dev"},{"key":"10.1016\/j.ejca.2026.116684_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10637-024-01446-y","article-title":"A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [(14)C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants","volume":"42","author":"Hanley","year":"2024","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejca.2026.116684_bib21","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116684_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/cpdd.967","article-title":"Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers","volume":"10","author":"Zhang","year":"2021","journal-title":"Clin Pharm Drug Dev"},{"key":"10.1016\/j.ejca.2026.116684_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2967\/jnumed.113.127100","article-title":"Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling","volume":"55","author":"Pruszynski","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2026.116684_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.116684_bib27","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib29","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116684_bib31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib32","article-title":"Abstract CT265: Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116684_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41698-024-00698-4","article-title":"A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation","volume":"8","author":"Thavaneswaran","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116684_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:18:25Z","timestamp":1776125905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"alternative-id":["S0959804926004648"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116684","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ia\/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116684"}}